In 2013, statin guidelines in Canada and Europe supported the use of statin to achieve a steady-state of LDL with ≥ 50% reduction, whereas present US guidelines supporter the use of statin that decrease LDL Less and more than 50% in moderate and high intensity, respectively 6. Current guidelines focus on lowering LDL cholesterol as the main goal of statin therapy to reduce the risk of CVD 11. More recently, literature has emerged that offers contradictory findings of the effects of statin.
However, the risk remains among statin-treated individuals and is known as "remaining risk" 10. Therefore, treatments with severe lipid reduction provide further clinical benefit and accelerate the improvement of atherosclerosis, which may lead to a decrease in cardiovascular events 8, 9. Recent evidence suggests that a sharp decline in the levels of LDL-C that is obtained with statins not only increases lipid profiles improvement but also significantly prevented the incidence of cardiovascular events compared to conventional lipid-lowering treatments for high-risk patients 5.This finding is supported by many scientists working on patients who were treated with a statin 6, 7. These groups of inhibitors, by preventing the function of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, play an imperative role in reducing cholesterol and declining the risk of developing atherosclerosis plaques and heart attacks 4. Over the past few decades, statin derivatives have been used with safely and increasingly clinical advantage in keep away patient from the threat of CVD. Dyslipidemia is generally seen as a factor strongly related to CVD and elevated low-density lipoprotein cholesterol (LDL-C) has been recognized as the key lipid feature in these circumstances 2, 3. CVD is affected by many factors such as age, hypertension, diabetes mellitus, dyslipidemia, insufficient activity, BMI, diet, and smoking 1. It seems likely that the achievement of a therapeutic target for serum lipids such as LDL-C improved is far more cost-effective and would be able to reach the target LDL as well changing the type and intensity of statins.Ĭardiovascular disease (CVD) has been thought of as the first cause of death in non-communicable disorders with extends of urbanization and industrial lifestyle.
LDL-C reduction after statin consumption was estimated about one-third of the studied population. In general, LDL-C goal achievement was greatest with moderate-intensity statin use.
The frequency of patient had achievement LDL goal lower in high-intensity pattern (N = 13, 2.3%), compared with moderate (N = 496, 86.1%) and low-intensity patterns (N = 67, 11.6%). The results showed that the proportion of patients meeting total LDL-C goal values according to the guidelines was 43.4%. Over half the populations (57.6%) were in the very-high CVD risk group. Three patterns of statin use (high/moderate/low-intensity statin therapy) in all patients were examined and attainments of LDL-C goal in cardiovascular risk groups have been demonstrated. Patients were classified and examined LDL-C values and the proportion reaching targets according to the American Association of Clinical Endocrinologists guideline. In the cross-sectional study, 585 patients treated with statin therapy referring to the heart clinic of Birjand were recruited. Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories.